Katherine Kudrycki, Ph.D. contributes more than 20 years of scientific expertise in dermatological science, inflammation, signal transduction, and gene expression research
SAN CARLOS, Calif., Nov. 13, 2013 /PRNewswire/ — Dr. Kudrycki brings over 20 years of scientific expertise in dermatological science, inflammation, signal transduction, and gene expression research. In addition, she has extensive experience applying mathematical models of biological and physiological systems to accelerate product development for biotechnology, pharmaceutical, and consumer product companies. Before joining Rosa, Dr. Kudrycki worked as a Senior Scientist at Entelos Holdings, where she developed mechanistic computational models and conducted in silico research in a variety of therapeutic areas, including dermatology, cardiovascular disease, oncology, rheumatoid arthritis, and asthma. Formerly, she conducted scientific basic research in dermatology at Unilever Research, US, and developed dermotoxicity assays to assess barrier function at Xgene Corp. Dr. Kudrycki holds a Ph.D. in Molecular Genetics from the University of Cincinnati School of Medicine. Following her Ph.D., she completed a post-doctoral fellowship at the Roche Institute of Molecular Biology.
(Logo: http://photos.prnewswire.com/prnh/20131113/PH15953LOGO)
"We are pleased to have Dr. Kudrycki join Rosa; she will extend and reinforce our current expertise, and she brings a strong scientific and client-based focus," said Dr. Ron Beaver, PhD, Rosa's Cofounder, Chairman, and CEO.
"I am delighted to join Rosa," Katherine added. "I am extremely impressed with the quality of biological modeling and research services offered by Rosa. I look forward to working with Rosa's dynamic, agile, highly experienced team, and the many clients Rosa supports. The quality and experience of Rosa's leadership team and the track record of successful delivery to clients are the key characteristics of this successful, growing company."
Rosa helps clients with their critical decisions – from preclinical through clinical development – with the creation and use of mathematical models that simulate normal and disease physiology, drug action, patient variability, and trial outcomes. To address the full spectrum of R&D related challenges, Rosa offers customized approaches: classic pharmacokinetic/pharmacodynamic (PK/PD) models and Rosa's innovative PhysioPD™ models. With these capabilities, Rosa's clients participate in customized model creation, testing, and research simulations, retain the models, and acquire the ability to perform model research to inform decisions and better understand implications for their drug development programs. Rosa's staff has unparalleled professional experience in applying modeling and simulation to accelerate drug development and have completed hundreds of engagements in virtually all therapeutic areas. The Rosa team is unique in its breadth and depth of disease area experience, including metabolism, oncology, inflammation, immunology, CNS, dermatology, and antibacterial biology. For information, visit www.rosaandco.com.
Contact:
Sharan Pagano
978-995-2805
Email